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developments in imaging and technology may further improve 
the therapeutic index. 
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Purpose or Objective: Surgery represents the treatment of 
choice for meningiomas. However, complete resection is 
often not possible, and recurrence is common. Radiation 
therapy (RT) can be prescribed as an alternative treatment to 
surgery for low-grade meningiomas, or in the 
recurrent/adjuvant setting. Differentiation between normal 
tissue, i.e. meninges, post-operative changes and residual 
viable tumor can be difficult using MR and CT imaging alone. 
We evaluated the impact of 68Ga-Dotatoc-PET imaging on 
treatment planning including potential benefit in terms of 
outcome. 
 
Material and Methods: We analyzed 15 patients with WHO I 
meningiomas of different localizations. All patients were 
treated with fractionated stereotactic radiotherapy (FSRT) 
with a total dose of 54 Gy and a single dose of 1.8 Gy. An 
advanced radiation oncologist delineated gross tumor volume 
(GTV) independently once based on diagnostic CT and MRI 
only (GTV_MR/CT), and a second time complemented by data 
of diagnostic 68Ga-Dotatoc-PET (GTV_PET). For image fusion 
and target definition BrainLab iPlan RT® software (Munich, 
Germany) was used. The intersection and union volumes of 
both GTVs (GTV_inter, GTV_union), were calculated. 
 
Results: In 11 of 15 patients (73%) the additional data gained 
by 68Ga-Dotatoc-PET led to a lager GTV. In four patients 
(27%) GTV_PET was smaller than GTV_MR/CT. The mean 
intersection of both GTVs was 58.6%. Hence, 41.4% of the 
GTV_PET was contributed only due to information from 68Ga-
Dotatoc-PET. About 22.6% of the GTV_MR/CT was not 
delineated in the GTV_PET volume because no increased 
tracer enhancement could be detected in these parts. Our 
first analyses of overall and progression free survival showed 
no significance in patients with a 68Ga-Dotatoc-PET for 
tumor delineation during treatment planning. 
 
Conclusion: 68Ga-Dotatoc-PET improves the detection of 
residual or recurrent tumor cells especially in patients with 
meningioma of the skull base and the sphenoorbital region. In 
addition it helps to spare normal tissue in patients with large 
tissue defects after operation. However, the interobserver 
variability must be taken into account. The data will now be 
correlated with OS and further analyzed concerning the 
standard uptake values (SUV) of the PET-images to assess if a 
threshold value can be recommended for meningioma 
detection and delineation. 
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Purpose or Objective: The latency, overall extent, and rate, 
of distant brain failure for patients undergoing SRS for 
melanoma brain metastases is not well characterized. We 
evaluated the impact of multiple pre-treatment parameters 
including age, KPS, gender, extracranial disease status (ECD), 
initial number of metastases, initial aggregate tumor volume, 
and B-raf V600E status, on distant brain failure. We also 
evaluated the impact of WBRT performed before, combined 
with, or after SRS. 
 
Material and Methods: The retrospective study population 
included 54 melanoma patients with brain metastases treated 
with SRS between 11/2008 and 01/2014. The distant brain 
metastasis-free survival (DBMFS) was defined as latency in 
months from initial SRS to first subsequent radiographic 
evidence of new brain metastasis. The extent of overall 
distant brain failure (ODBF) was defined as the total number 
of new metastases that developed following initial SRS 
treatment. The distant brain failure rate (DBFR) was defined 
as the ODBF/RFI, where RFI was defined as the maximum 
radiographic follow-up interval in months. Kaplan Meir 
analysis was used to evaluate DBMFS and Log Rank test was 
used to determine the significance (p-value <0.05 was 
considered significant). For ODBF and DBFR, Independent 
sample t-test and one-way ANOVA were used for statistical 
evaluation. 
 
Results: The median overall DBMFS was 5.69 months. A 
significant difference in median DBMFS was observed for 
patients with KPS<70 vs KPS >70 (2.24 vs. 10.44 months, p 
<0.022). Females had significantly worse DBMFS than males 
(5.96 vs. 17.96 months, p<0.009). The initial number of 
metastases, total initial metastasis volume, ECD status, and 
B-raf V600E mutation status, were associated with no 
significant difference in DBMFS. The ODBF was also worse for 
females than males (P<0.002). The DBFR was worse for 
females (p<0.049), and those with c-kit mutation (P<0.024). 
WBRT had no significant effect on DBMFS, ODBF or DBFR in 
the study population. 
 
Conclusion: Characterization of the risk of distant brain 
failure is important to treatment selection, prognosis and 
follow-up. Among patients with melanoma brain metastases 
treated with SRS, our study found that female gender and a 
KPS<70 was associated with a significantly decreased latency 
to distant brain failure. In addition, female gender was 
associated with greater overall number of distant brain 
metastases and rate of distant brain failure. Mutations in c-
kit but not b-raf were found to be associated with increased 
distant brain failure. Further study is underway to examine 
the overall clinical prognostic relevance of these findings. 
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Purpose or Objective: In concern gliosarcoma management, 
the aims of this multicentre retrospective study were to 
identify prognostic or therapeutic factors impacting on 
overall survival. 
 
